Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial

Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial

Background:The benefits of pharmacotherapy with tiotropium HandiHaler 18 μg for patients with chronic obstructive pulmonary disease (COPD) have been previously demonstrated. However, few data exist regarding the treatment of moderate disease (Global Initiative for Chronic Obstructive Lung Disease (G...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:NPJ primary care respiratory medicine 2014, Vol.2014 (24), p.1-8
Hauptverfasser: Troosters, Thierry, Sciurba, Frank C, Decramer, Marc, Siafakas, Nikos M, Klioze, Solomon S, Sutradhar, Santosh C, Weisman, Idelle M, Yunis, Carla
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 8
container_issue 24
container_start_page 1
container_title NPJ primary care respiratory medicine
container_volume 2014
creator Troosters, Thierry
Sciurba, Frank C
Decramer, Marc
Siafakas, Nikos M
Klioze, Solomon S
Sutradhar, Santosh C
Weisman, Idelle M
Yunis, Carla
description Background:The benefits of pharmacotherapy with tiotropium HandiHaler 18 μg for patients with chronic obstructive pulmonary disease (COPD) have been previously demonstrated. However, few data exist regarding the treatment of moderate disease (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II).Aims:To determine whether tiotropium improves lung function/patient-reported outcomes in patients with GOLD stage II COPD naive to maintenance therapy.Methods:A randomised 24-week double-blind placebo-controlled trial of tiotropium 18 μg once daily (via HandiHaler) was performed in maintenance therapy-naive patients with forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio
format Article
fullrecord <record><control><sourceid>kuleuven</sourceid><recordid>TN_cdi_kuleuven_dspace_123456789_455216</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>123456789_455216</sourcerecordid><originalsourceid>FETCH-kuleuven_dspace_123456789_4552163</originalsourceid><addsrcrecordid>eNqVjLtOAzEQRS1EJCLIP0xHgVayvXEWaAOIDor0q8nuoEzwS-vZAH-PCwpKqO5D594ztbTaucZoo89_-Qu1KuWotTbWdZ21SxV2nGRKmecAHCGjMEUp8MFygJBGmlAIti-vDxCRTwSSICBHoYhxqPFQifx1DwgTxjEFLjRC9jjQPjVDivXc-1rJxOiv1OINfaHVj16q66fH3fa5eZ89zSeK_VhynfbGtmu36W7v-rVz1mza_5A3fyN7-ZT2G-tyWl4</addsrcrecordid><sourcetype>Institutional Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial</title><source>Lirias (KU Leuven Association)</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Troosters, Thierry ; Sciurba, Frank C ; Decramer, Marc ; Siafakas, Nikos M ; Klioze, Solomon S ; Sutradhar, Santosh C ; Weisman, Idelle M ; Yunis, Carla</creator><creatorcontrib>Troosters, Thierry ; Sciurba, Frank C ; Decramer, Marc ; Siafakas, Nikos M ; Klioze, Solomon S ; Sutradhar, Santosh C ; Weisman, Idelle M ; Yunis, Carla</creatorcontrib><description>Background:The benefits of pharmacotherapy with tiotropium HandiHaler 18 μg for patients with chronic obstructive pulmonary disease (COPD) have been previously demonstrated. However, few data exist regarding the treatment of moderate disease (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II).Aims:To determine whether tiotropium improves lung function/patient-reported outcomes in patients with GOLD stage II COPD naive to maintenance therapy.Methods:A randomised 24-week double-blind placebo-controlled trial of tiotropium 18 μg once daily (via HandiHaler) was performed in maintenance therapy-naive patients with forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio &lt;0.7 and post-bronchodilator FEV1 ⩾50 and &lt;80%.Results:A total of 457 patients were randomised (238 tiotropium, 219 placebo; mean age 62 years; FEV1 1.93 l (66% predicted)). Tiotropium was superior to placebo in mean change from baseline in post-dose FEV1 area under the curve from 0 to 3 h (AUC0-3h) at week 24 (primary endpoint): 0.19 vs. -0.03 l (least-squares mean difference 0.23 l, P&lt;0.001). FVC AUC0-3h, trough and peak FEV1 and FVC were significantly improved with tiotropium versus placebo (P&lt;0.001). Compared with placebo, tiotropium provided numerical improvements in physical activity (P=NS). Physician's Global Assessment (health status) improved (P=0.045) with less impairment on the Work Productivity and Activity Impairment questionnaire (P=0.043) at week 24. The incidence of exacerbations, cough, bronchitis and dyspnoea was lower with tiotropium than placebo.Conclusions:Tiotropium improved lung function and patient-reported outcomes in maintenance therapy-naive patients with GOLD stage II COPD, suggesting benefits in initiating maintenance therapy early.</description><identifier>ISSN: 2055-1010</identifier><identifier>EISSN: 2055-1010</identifier><language>eng</language><publisher>NATURE PORTFOLIO</publisher><ispartof>NPJ primary care respiratory medicine, 2014, Vol.2014 (24), p.1-8</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,315,776,780,4010,27837</link.rule.ids></links><search><creatorcontrib>Troosters, Thierry</creatorcontrib><creatorcontrib>Sciurba, Frank C</creatorcontrib><creatorcontrib>Decramer, Marc</creatorcontrib><creatorcontrib>Siafakas, Nikos M</creatorcontrib><creatorcontrib>Klioze, Solomon S</creatorcontrib><creatorcontrib>Sutradhar, Santosh C</creatorcontrib><creatorcontrib>Weisman, Idelle M</creatorcontrib><creatorcontrib>Yunis, Carla</creatorcontrib><title>Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial</title><title>NPJ primary care respiratory medicine</title><description>Background:The benefits of pharmacotherapy with tiotropium HandiHaler 18 μg for patients with chronic obstructive pulmonary disease (COPD) have been previously demonstrated. However, few data exist regarding the treatment of moderate disease (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II).Aims:To determine whether tiotropium improves lung function/patient-reported outcomes in patients with GOLD stage II COPD naive to maintenance therapy.Methods:A randomised 24-week double-blind placebo-controlled trial of tiotropium 18 μg once daily (via HandiHaler) was performed in maintenance therapy-naive patients with forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio &lt;0.7 and post-bronchodilator FEV1 ⩾50 and &lt;80%.Results:A total of 457 patients were randomised (238 tiotropium, 219 placebo; mean age 62 years; FEV1 1.93 l (66% predicted)). Tiotropium was superior to placebo in mean change from baseline in post-dose FEV1 area under the curve from 0 to 3 h (AUC0-3h) at week 24 (primary endpoint): 0.19 vs. -0.03 l (least-squares mean difference 0.23 l, P&lt;0.001). FVC AUC0-3h, trough and peak FEV1 and FVC were significantly improved with tiotropium versus placebo (P&lt;0.001). Compared with placebo, tiotropium provided numerical improvements in physical activity (P=NS). Physician's Global Assessment (health status) improved (P=0.045) with less impairment on the Work Productivity and Activity Impairment questionnaire (P=0.043) at week 24. The incidence of exacerbations, cough, bronchitis and dyspnoea was lower with tiotropium than placebo.Conclusions:Tiotropium improved lung function and patient-reported outcomes in maintenance therapy-naive patients with GOLD stage II COPD, suggesting benefits in initiating maintenance therapy early.</description><issn>2055-1010</issn><issn>2055-1010</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>FZOIL</sourceid><recordid>eNqVjLtOAzEQRS1EJCLIP0xHgVayvXEWaAOIDor0q8nuoEzwS-vZAH-PCwpKqO5D594ztbTaucZoo89_-Qu1KuWotTbWdZ21SxV2nGRKmecAHCGjMEUp8MFygJBGmlAIti-vDxCRTwSSICBHoYhxqPFQifx1DwgTxjEFLjRC9jjQPjVDivXc-1rJxOiv1OINfaHVj16q66fH3fa5eZ89zSeK_VhynfbGtmu36W7v-rVz1mza_5A3fyN7-ZT2G-tyWl4</recordid><startdate>2014</startdate><enddate>2014</enddate><creator>Troosters, Thierry</creator><creator>Sciurba, Frank C</creator><creator>Decramer, Marc</creator><creator>Siafakas, Nikos M</creator><creator>Klioze, Solomon S</creator><creator>Sutradhar, Santosh C</creator><creator>Weisman, Idelle M</creator><creator>Yunis, Carla</creator><general>NATURE PORTFOLIO</general><scope>FZOIL</scope></search><sort><creationdate>2014</creationdate><title>Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial</title><author>Troosters, Thierry ; Sciurba, Frank C ; Decramer, Marc ; Siafakas, Nikos M ; Klioze, Solomon S ; Sutradhar, Santosh C ; Weisman, Idelle M ; Yunis, Carla</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kuleuven_dspace_123456789_4552163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Troosters, Thierry</creatorcontrib><creatorcontrib>Sciurba, Frank C</creatorcontrib><creatorcontrib>Decramer, Marc</creatorcontrib><creatorcontrib>Siafakas, Nikos M</creatorcontrib><creatorcontrib>Klioze, Solomon S</creatorcontrib><creatorcontrib>Sutradhar, Santosh C</creatorcontrib><creatorcontrib>Weisman, Idelle M</creatorcontrib><creatorcontrib>Yunis, Carla</creatorcontrib><collection>Lirias (KU Leuven Association)</collection><jtitle>NPJ primary care respiratory medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Troosters, Thierry</au><au>Sciurba, Frank C</au><au>Decramer, Marc</au><au>Siafakas, Nikos M</au><au>Klioze, Solomon S</au><au>Sutradhar, Santosh C</au><au>Weisman, Idelle M</au><au>Yunis, Carla</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial</atitle><jtitle>NPJ primary care respiratory medicine</jtitle><date>2014</date><risdate>2014</risdate><volume>2014</volume><issue>24</issue><spage>1</spage><epage>8</epage><pages>1-8</pages><issn>2055-1010</issn><eissn>2055-1010</eissn><abstract>Background:The benefits of pharmacotherapy with tiotropium HandiHaler 18 μg for patients with chronic obstructive pulmonary disease (COPD) have been previously demonstrated. However, few data exist regarding the treatment of moderate disease (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II).Aims:To determine whether tiotropium improves lung function/patient-reported outcomes in patients with GOLD stage II COPD naive to maintenance therapy.Methods:A randomised 24-week double-blind placebo-controlled trial of tiotropium 18 μg once daily (via HandiHaler) was performed in maintenance therapy-naive patients with forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio &lt;0.7 and post-bronchodilator FEV1 ⩾50 and &lt;80%.Results:A total of 457 patients were randomised (238 tiotropium, 219 placebo; mean age 62 years; FEV1 1.93 l (66% predicted)). Tiotropium was superior to placebo in mean change from baseline in post-dose FEV1 area under the curve from 0 to 3 h (AUC0-3h) at week 24 (primary endpoint): 0.19 vs. -0.03 l (least-squares mean difference 0.23 l, P&lt;0.001). FVC AUC0-3h, trough and peak FEV1 and FVC were significantly improved with tiotropium versus placebo (P&lt;0.001). Compared with placebo, tiotropium provided numerical improvements in physical activity (P=NS). Physician's Global Assessment (health status) improved (P=0.045) with less impairment on the Work Productivity and Activity Impairment questionnaire (P=0.043) at week 24. The incidence of exacerbations, cough, bronchitis and dyspnoea was lower with tiotropium than placebo.Conclusions:Tiotropium improved lung function and patient-reported outcomes in maintenance therapy-naive patients with GOLD stage II COPD, suggesting benefits in initiating maintenance therapy early.</abstract><pub>NATURE PORTFOLIO</pub><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2055-1010
ispartof NPJ primary care respiratory medicine, 2014, Vol.2014 (24), p.1-8
issn 2055-1010
2055-1010
language eng
recordid cdi_kuleuven_dspace_123456789_455216
source Lirias (KU Leuven Association); DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access
title Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T19%3A42%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kuleuven&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tiotropium%20in%20patients%20with%20moderate%20COPD%20naive%20to%20maintenance%20therapy:%20a%20randomised%20placebo-controlled%20trial&rft.jtitle=NPJ%20primary%20care%20respiratory%20medicine&rft.au=Troosters,%20Thierry&rft.date=2014&rft.volume=2014&rft.issue=24&rft.spage=1&rft.epage=8&rft.pages=1-8&rft.issn=2055-1010&rft.eissn=2055-1010&rft_id=info:doi/&rft_dat=%3Ckuleuven%3E123456789_455216%3C/kuleuven%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true